# Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)

> **NCT00212004** · PHASE4 · TERMINATED · sponsor: **National Cerebral and Cardiovascular Center, Japan** · enrollment: 630 (actual)

## Conditions studied

- Diabetes Mellitus
- Myocardial Infarction

## Interventions

- **DRUG:** pioglitazone
- **OTHER:** control

## Key facts

- **NCT ID:** NCT00212004
- **Lead sponsor:** National Cerebral and Cardiovascular Center, Japan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2017-04
- **Final completion:** 2018-04
- **Target enrollment:** 630 (ACTUAL)
- **Why stopped:** Limited budget to continue this study
- **Last updated:** 2018-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00212004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00212004, "Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00212004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*